CA3143619A1 - Combination for the treatment of infections caused by mycoplasma genitalium - Google Patents

Combination for the treatment of infections caused by mycoplasma genitalium Download PDF

Info

Publication number
CA3143619A1
CA3143619A1 CA3143619A CA3143619A CA3143619A1 CA 3143619 A1 CA3143619 A1 CA 3143619A1 CA 3143619 A CA3143619 A CA 3143619A CA 3143619 A CA3143619 A CA 3143619A CA 3143619 A1 CA3143619 A1 CA 3143619A1
Authority
CA
Canada
Prior art keywords
gepotidacin
doxycycline
pharmaceutically acceptable
acceptable salt
mycoplasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3143619A
Other languages
English (en)
French (fr)
Inventor
Nicole SCANGARELLA-OMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CA3143619A1 publication Critical patent/CA3143619A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3143619A 2019-07-05 2020-07-03 Combination for the treatment of infections caused by mycoplasma genitalium Pending CA3143619A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962870990P 2019-07-05 2019-07-05
US62/870,990 2019-07-05
US202062985465P 2020-03-05 2020-03-05
US62/985,465 2020-03-05
PCT/EP2020/068754 WO2021004910A1 (en) 2019-07-05 2020-07-03 Combination for the treatment of infections caused by mycoplasma genitalium

Publications (1)

Publication Number Publication Date
CA3143619A1 true CA3143619A1 (en) 2021-01-14

Family

ID=71579551

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3143619A Pending CA3143619A1 (en) 2019-07-05 2020-07-03 Combination for the treatment of infections caused by mycoplasma genitalium

Country Status (8)

Country Link
US (1) US20220257615A1 (https=)
EP (1) EP3993796B1 (https=)
JP (1) JP7638263B2 (https=)
CN (1) CN114173789A (https=)
BR (1) BR112021024845A2 (https=)
CA (1) CA3143619A1 (https=)
ES (1) ES2981617T3 (https=)
WO (1) WO2021004910A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11917094B2 (en) * 2021-02-01 2024-02-27 Aptiv Technologies Limited Automatic control of smartphone driver mode using ultra-wideband communication
EP4288035A1 (en) * 2021-02-05 2023-12-13 GlaxoSmithKline Intellectual Property Development Limited Oral solid dose formulations
JP2025532252A (ja) 2022-09-26 2025-09-29 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 処置方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008240764C1 (en) * 2007-04-20 2011-10-20 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
US9993469B2 (en) 2013-05-28 2018-06-12 Morphochem Aktiengesellschaft Für Kombinatorishe Chemie Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
US10702521B2 (en) * 2014-08-22 2020-07-07 Glaxosmithkline Intellectual Property Development Limited Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones
WO2018195098A1 (en) * 2017-04-17 2018-10-25 Ohio State Innovation Foundation Type ii topoisomerase inhibitors and methods of making and using thereof

Also Published As

Publication number Publication date
BR112021024845A2 (pt) 2022-01-18
JP2022539583A (ja) 2022-09-12
JP7638263B2 (ja) 2025-03-03
EP3993796C0 (en) 2024-02-21
ES2981617T3 (es) 2024-10-09
WO2021004910A1 (en) 2021-01-14
US20220257615A1 (en) 2022-08-18
EP3993796A1 (en) 2022-05-11
EP3993796B1 (en) 2024-02-21
CN114173789A (zh) 2022-03-11

Similar Documents

Publication Publication Date Title
EP3993796B1 (en) Combination for the treatment of infections caused by mycoplasma genitalium
US9839634B2 (en) Antibacterial agents: combination of a rifamycin and a switch region inhibitor
CA3134801A1 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
Tomioka et al. Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex
US20230398139A1 (en) Methods and compositions for treating carbapenem-resistant klebsiella pneumoniae infections
EP1223935A1 (en) Methods of use of fluoroquinolone compounds against bacteria
CN101543506A (zh) 预防或治疗猪链球菌病的复方抗生素组合物
US7595328B2 (en) Methods of use of quinolone compounds against pneumococcal and Haemophilus bacteria
ES3004932T3 (en) Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
US20250099535A1 (en) Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus
US20240108620A1 (en) Treatment Regimen
Blondeau et al. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections
US20220184071A1 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
WO2014140988A1 (en) Rifaximin for use in the treating of vaginal infections.
KR20140091716A (ko) 박테리아 감염의 치료를 위한 약학적 조성물 및 키트
WO2018070874A1 (en) Means and methods for reducing or avoiding antibiotic resistance and spread of virulence in human pathogens
Wagenlehner et al. Urinary bactericidal activity of doripenem versus levofloxacin in patients with complicated urinary tract infections or pyelonephritis
Wada et al. Studies of fluoroquinolone-resistant escherichia coli isolated from urinary tract infections between 1994 and 2006 in japan

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240418

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250415

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20250422

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250625

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250805

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250808

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250915

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250915